Eczema (chronic) - alitretinoin: review decision - October 2012
Review of NICE Technology Appraisal Guidance No. 177; Alitretinoin for the treatment of severe chronic hand eczema
The Institute was proposing that TA177 should be transferred to the static guidance list.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute's Guidance Executive has decided to proceed with the proposal. TA177 will therefore be transferred to the static guidance list. However, if NICE is notified of a significant change to the evidence base at any stage within the next 5 years then this could trigger a review proposal.
This page was last updated: 12 October 2012